MORGAN STANLEY PLC/CALL/AMGEN/480/0.1/17.01.25 | Market Closed - Börse Stuttgart 10:09:58 21/05/2024 BST | ||
| 0.199 EUR | -7.87% |
|
| Current month | +53.08% | ||
| 1 month | +28.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 21/05/24 | 0.199 | -7.87% |
| 20/05/24 | 0.216 | +4.85% |
| 17/05/24 | 0.206 | -6.36% |
| 16/05/24 | 0.22 | -4.35% |
| 15/05/24 | 0.23 | +11.11% |
Delayed Quote Börse Stuttgart
Last update May 21, 2024 at 10:09 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB0FW3 |
| ISIN | DE000MB0FW39 |
| Date issued | 10/11/2022 |
| Strike | 480 $ |
| Maturity | 17/01/2025 (241 Days) |
| Parity | 10 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.06 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.022 € |
| Spread % | 9.05% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
314.8
USD
Average target price
316.1
USD
Spread / Average Target
+0.39%
- Stock Market
- Warrants
- Warrant
